New possibilities of pathogenetic therapy for allergic rhinitis
https://doi.org/10.21518/2079-701X-2018-20-89-91
Abstract
Allergic rhinitis is one of the most common human diseases that affect patients’ quality of of life. There has been a significant increase in incidence rates related to allergic rhinitis in the Russian Federation and the world. Second-generation antihistamines having high H1-receptor affinity constitute the main pharmacological group for the treatment of allergic rhinitis. The article presents an overview of Bilastin as a novel drug of the above group.
About the Authors
A. A. Krivopalov
Saint-Petersburg Research Institute of Ear, Throat, Nose and Speech of the Ministry of Healthcare of Russia, St. Petersburg
Russian Federation
Russian Federation
S. A. Rebrova
Saint-Petersburg Research Institute of Ear, Throat, Nose and Speech of the Ministry of Healthcare of Russia, St. Petersburg
Russian Federation
Russian Federation
L. I. Krivopalova
Petersburg Metro Polyclinic, St. Petersburg
Russian Federation
Russian Federation
References
1. Lopatin AS. Rhinitis. M.: Literra. 2010
2. Goryachkina LA, Kashkin EP, Terekhova EP, et al. Clinical allergology and immunology: a guide for practitioners. Under the editorship of Goryachkina LA and Kashkina EP. M.: Miklosh, 2009: 121.
3. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA²LEN and AllerGen. Allergy, 2008, 63(Suppl. 86): 8-160.
4. Vasilevsky IV. Rehabilitation of children and adolescents with diseases of the respiratory, digestive, renal, cardiovascular system and allergic diseases in polyclinic conditions. Minsk: BelMAPO, 2007: 157-171.
5. WHO Fact sheet No. 310 (July 2015) / WHO. Global Health Observatory data repository. Available at: http://www.who.int/gho/database/en/
6. Bank of documents. Ministry of Healthcare of the Russian Federation. Available at: http://old.rosminzdrav. ru/docs.
7. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol, 1988, 94: 187—191.
8. Kellaway CH, Trethewie ER. The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol, 1940, 30: 121—145.
9. Brocklehurst W. The release of histamine and formation of a slow reacting substance (SRS-A) during anaphylactic shock. J Physiol, 1960, 151: 416—435.
10. Sadaba B, Gomez-Guiu A, Azanza JR, Ortega I, Valiente R. Oral availability of bilastine. Clin Drug Investig, 2013, 33: 375-381.
11. Lucero ML, Gonzalo A, Mumford R, Betanzos M, Alejandro A. An overview of bilastine metabolism during preclinical investigations. Drug Chem Toxicol, 2012, 35(suppl l): 18-24.
12. Graff C, Struijk JJ, Kanters JK, Andersen MP, Toft E, Tyl B. Effects ofbilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Investig, 2012, 32: 339-351.
13. Church MK. Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf, 2011, V. 10(5): 779-793.
14. Corcostegui R, Labeaga L, Innerarity A, Berisa A, Oijales A. In vivo pharmacological characterisation of bilastine, a potent and selective histamine HI receptor antagonist. Drugs R D, 2006, 7: 219-231.
15. Sastre J, Mullol J, Valero A; Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin, 2012, 28: 121-130.
16. Tashiro M, Sakurada Y, Iwabuchi K, et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine HI-receptor occupancy using 1 lC-doxepin positron emission tomography. J Clin Pharmacol, 2004, 44: 890-900.
17. Zuberbier T, Oanta A, Bogacka E. Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg forthe treatment of chronic idiopathic urticaria: a multi-centre, doubleblind, randomized, placebo-controlled study. Allergy, 2010, 65: 516-528.
18. Prepageran N, Wangde Y, Nair G, Maurer M. The status quo and unmet needs in the management of allergic rhinitis and chronic lhinosinusitis: a Malaysian perspective. Asia Рас Allergy, 2014, 4: 142-148.
19. Dykewicz MS, Fineman S, Skoner DP. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol, 1998, 81: 478–518.
Review
For citations:
Krivopalov AA, Rebrova SA, Krivopalova LI. New possibilities of pathogenetic therapy for allergic rhinitis. Meditsinskiy sovet = Medical Council. 2018;(20):89-91. (In Russ.) https://doi.org/10.21518/2079-701X-2018-20-89-91
Views:
665
Email this article 